Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 24
Filtre
1.
Rev. bras. oftalmol ; 80(4): e0015, 2021. graf
Article Dans Anglais | LILACS | ID: biblio-1288631

Résumé

ABSTRACT The authors present a case of lupus miliaris disseminatus faciei , a rare skin disease of unknown etiology, which may cause unaesthetic scarring due to its difficult treatment. The histopathological examination of epithelioid granulomas with caseating necrosis, together with the clinical features, are important for diagnosis and early treatment with better results. Despite difficult and unsatisfactory treatment, there are ongoing studies on therapy to improve aesthetic and social impairment. This case report describes an initial misdiagnosis delaying appropriate treatment, and highlights the value of physical examination and clinical judgment for another pathological examination, whenever necessary, aiming at better treatment outcomes in daily practice.


RESUMO Os autores apresentam um caso de lupus miliaris disseminatus faciei , uma dermatose rara, de etiologia desconhecida, que pode deixar cicatrizes não estéticas, pela dificuldade de tratamento. O exame histopatológico de granulomas compostos por células epitelioides, com necrose caseosa, e as características clínicas, são importantes para o diagnóstico e tratamento precoce, com melhores resultados. Apesar do tratamento difícil e insatisfatório, há estudos em andamento sobre terapias para melhorar o comprometimento estético e social. Este relato de caso descreve um diagnóstico inicial errôneo, que atrasou o tratamento adequado, e destaca o valor do exame físico e raciocínio clínico para solicitar outro exame anatomopatológico, quando necessário, de forma a obter melhores desfechos com o tratamento, na prática diária.


Sujets)
Humains , Femelle , Adulte , Maladies de la paupière/anatomopathologie , Maladies de la paupière/traitement médicamenteux , Dermatoses faciales/anatomopathologie , Dermatoses faciales/traitement médicamenteux , Tétracycline/usage thérapeutique , Prednisone/usage thérapeutique , Isotrétinoïne/usage thérapeutique , Cicatrice , Tacrolimus/usage thérapeutique , Rosacée/anatomopathologie , Rosacée/traitement médicamenteux , Dapsone/usage thérapeutique , Granulome/anatomopathologie , Granulome/traitement médicamenteux , Lupus tuberculeux/anatomopathologie , Lupus tuberculeux/traitement médicamenteux , Minocycline/usage thérapeutique
2.
An. bras. dermatol ; 95(supl.1): 53-69, Nov.-Dec. 2020. tab
Article Dans Anglais | LILACS | ID: biblio-1152779

Résumé

Abstract Background: Rosacea is a chronic inflammatory disease of the skin, relatively more frequent in women over 30 with a low phototype and proven genetic predisposition. Although its etiology is unknown and possibly multifactorial, the immunological abnormality, associated with neurovascular dysregulation and triggering factors, are important elements in its pathophysiology, which lead to the main changes of inflammation, vasodilation, and angiogenesis that are responsible for the clinical manifestations. Despite the lack of cure, numerous therapeutic options are available for the different clinical presentations of the disease, with satisfactory responses. Objective: To reach a consensus, with recommendations from experts, on the therapeutic management of rosacea suitable to the Brazilian setting. Methods: The study was conducted by five specialized dermatologists from university centers, representatives of the different Brazilian regions, with experience in rosacea, who were appointed by the Brazilian Society of Dermatology. Based on the adapted DELPHI methodology, the experts contributed through an updated bibliographic review of the scientific evidence, combined with personal experiences. Results: The group of experts reached a consensus on the relevant aspects in the therapeutic management of rosacea, providing information on epidemiology, pathophysiology, triggering factors, clinical condition, classification, quality of life, and comorbidities. Consensus was defined as approval by at least 90% of the panel. Conclusion: Despite the impossibility of cure, there are several therapeutic alternatives specific to each patient that provide excellent results, with chances of total improvement and long periods of remission, promoting a positive impact on quality of life. This consensus provides detailed guidance for clinical practice and therapeutic decisions in rosacea.


Sujets)
Humains , Rosacée/diagnostic , Rosacée/traitement médicamenteux , Dermatologie , Qualité de vie , Brésil , Consensus
3.
Arq. bras. oftalmol ; 83(2): 109-112, Mar.-Apr. 2020. tab
Article Dans Anglais | LILACS | ID: biblio-1088962

Résumé

ABSTRACT Purpose: To compare the impact of ocular changes between systemic treatment with doxycycline and low-dose oral isotretinoin in patients with moderate-to-severe papulopustular rosacea. Methods: Patients were randomized to receive either isotretinoin 0.3-0.4 mg/kg (group A) or doxycycline 100 mg/day (group B) for 16 weeks. Ocular symptoms were searched and evaluated, including best-corrected visual acuity (BCVA), Schirmer test, breakup time, rose bengal staining score, and meibomian gland dysfunction grading. The patients were retested at the end of treatment. Results: The present study included 39 patients (30 females and 9 males). Best-corrected visual acuity was > 20/30 in >90% of patients in both groups and did not change after treatment. After treatment, improvement in ocular symptoms and meibomian gland dysfunction was more pronounced in group B (p<0.05); the other parameters did not reach statistical significance. Conclusion: Doxycycline improved meibomian gland dysfunction, ocular symptoms, and ocular surface in patients with rosacea. Even though some patients experienced worsening meibomian gland dysfunction and symptoms, no subject experienced any serious complications after administration of low-dose isotretinoin.


RESUMO Objetivos: Comparar o impacto das alterações oculares entre o tratamento sistêmico de doxiciclina e isotretinoína em baixa dosagem em pacientes com rosácea papulopustulosa moderada a grave. Métodos: Os pacientes form randomizados para receber isotretinoína 0,3 a 0,4 mg/kg (grupo A) ou doxiciclina 100mg/dia (grupo B) por 16 semanas. Os sintomas oculares foram pesquisados e avaliados, incluindo melhor acuidade visual corrigida, teste de Schirmer, tempo de ruptura do filme lacrimal, coloração de rosa bengala e graduação da disfunção de glândula de Meibomius. Os pacientes foram novamente testados no final do tratamento. Resultados: O presente estudo incluiu 39 pacientes (30 mulheres e 9 homens). A melhor acuidade visual corrigida foi >20/30 em >90% dos pacientes em ambos os grupos e não se alterou após o tratamento. A melhora dos sintomas oculares e da disfunção de glândula de Meibomius foi mais pronunciada no grupo B (p<0,05) após o tratamento; as demais variáveis não atingiram significância estatística. Conclusão: A doxiciclina melhorou a disfunção de glândula de Meibomius, os sintomas oculares e a superfície ocular de pa cientes com rosácea. Mesmo que alguns pacientes tenham piorado a disfunção e os sintomas da glândula de Meibomius, nenhum indivíduo apresentou complicações graves após a admi nistração de baixas doses de isotretinoína.


Sujets)
Humains , Mâle , Femelle , Adulte , Adulte d'âge moyen , Sujet âgé , Jeune adulte , Isotrétinoïne/administration et posologie , Doxycycline/administration et posologie , Rosacée/traitement médicamenteux , Produits dermatologiques/administration et posologie , Dysfonctionnement des glandes de Meibomius/traitement médicamenteux , Antibactériens/administration et posologie , Indice de gravité de la maladie , Acuité visuelle , Administration par voie orale , Résultat thérapeutique , Rosacée/physiopathologie , Oeil/effets des médicaments et des substances chimiques , Dysfonctionnement des glandes de Meibomius/physiopathologie , Glandes de Meibomius/effets des médicaments et des substances chimiques
4.
Arq. bras. oftalmol ; 81(6): 466-470, Nov.-Dec. 2018. tab
Article Dans Anglais | LILACS | ID: biblio-973856

Résumé

ABSTRACT Purpose: This study reports the effects of combined use of oral doxycycline and topical cyclosporine on ocular signs, symptoms, and tear film parameters in rosacea patients. Methods: Fifty-four right eyes of 54 patients were included in this study. All patients underwent full ophthalmologic examination-including best corrected visual acuity measurement, slit-lamp anterior segment and fundus examination, tear film break-up time, and Schirmer test-before treatment and six months post-treatment. Patients were divided into two treatment groups. The first group was treated with oral doxycycline 100 mg twice daily for the first month and once daily for the following two months. The second group received topical 0.05% cyclosporine emulsion drops twice daily for six months in addition to the oral doxycycline treatment regimen. All patients received preservati ve-free artificial tear drops, warm compress, eyelash cleaning, and topical corticosteroid drops three times daily for one month. Results: A significant improvement in ocular signs and symptoms was recorded for all patients in groups 1 and 2 after treatment. There was not a significant difference in terms of itching, burning, meibomian gland inspissation, corneal neovascularization, and conjunctival hyperemia score changes between groups 1 and 2. The increases in Schirmer test and break-up time scores were significantly higher in group 2 than in group 1. Conclusions: Our results support the finding that topical cyclosporine in addition to the standard regimen improves tear function, as shown by Schirmer test and break-up time scores, in ocular rosacea patients.


RESUMO Objetivo: Este estudo relata os efeitos do uso combinado de doxiciclina oral e ciclosporina tópica sobre sinais e sintomas oculares e sobre parâmetros do filme lacrimal em pacientes com rosácea. Métodos: Cinquenta e quatro olhos direitos de 54 pacientes foram incluídos no estudo. Todos os pacientes foram submetidos a exame oftalmológico completo - incluindo a melhor medida da acuidade visual corrigida, segmento anterior em lâmpada de fenda e exame de fundo de olho, tempo de ruptura do filme lacrimal e teste de Schirmer - antes do tratamento e após seis meses de tratamento. O primeiro grupo foi tratado com doxiciclina oral 100 mg duas vezes ao dia no primeiro mês e uma vez ao dia nos dois meses seguintes. O segundo grupo recebeu gotas tópicas de emulsão de ciclosporina a 0,05% duas vezes ao dia por seis meses, além do tratamento com doxiciclina por via oral. Todos os pacientes receberam gotas de lágrima artificial sem conservantes, compressas mormas, limpeza de cílios e gotas de corticosteróide tópico três vezes ao dia durante um mês. Resultados: Uma melhora significativa nos sinais e sintomas oculares foi registrada para todos os pacientes do grupo 1 e 2 após o tratamento. Não houve diferença significativa em termos de prurido, queimação, inspeção da glândula meibomiana, neovascularização da cór nea e alterações na pontuação da hiperemia conjuntival entre os grupos 1 e 2. O teste de Schirmer e o aumento do tempo de ruptura no grupo 2 foram significativamente maiores do que no grupo 1. Conclusões: Os autores concluíram que os resultados apoiam a descoberta de que a ciclosporina tópica, além do tratamento padrão, melhora a função lacrimal como demonstrado pelo teste de Schirmer e o tempo de ruptura em pacientes com rosácea ocular.


Sujets)
Humains , Mâle , Femelle , Adulte , Adulte d'âge moyen , Ciclosporine/usage thérapeutique , Doxycycline/usage thérapeutique , Rosacée/traitement médicamenteux , Immunosuppresseurs/usage thérapeutique , Antibactériens/usage thérapeutique , Larmes/effets des médicaments et des substances chimiques , Larmes/physiologie , Administration par voie orale , Études rétrospectives , Ciclosporine/administration et posologie , Ciclosporine/pharmacologie , Doxycycline/administration et posologie , Doxycycline/pharmacologie , Techniques de diagnostic ophtalmologique , Association de médicaments , Administration par voie ophtalmique , Antibactériens/administration et posologie , Antibactériens/pharmacologie
5.
An. bras. dermatol ; 91(5,supl.1): 151-153, Sept.-Oct. 2016. graf
Article Dans Anglais | LILACS | ID: biblio-837927

Résumé

Abstract Rosacea fulminans or pyoderma faciale is a rare cutaneous disorder that usually affects women usually between the ages of 15-46. The disease is characterized by sudden onset of papules, pustules, cysts, and painful coalescing nodules with red-cyanotic centrofacial erythema. Although its etiology remains unknown, hormonal, immunological, and vascular factors have been reported. Early diagnosis and prompt treatment should minimize unsightly scars. We report a case of a 33-year-old female patient treated with traditional doses of doxycycline, with improvement of the lesions and regression of the condition in two months.


Sujets)
Humains , Femelle , Adulte , Doxycycline/usage thérapeutique , Rosacée/anatomopathologie , Rosacée/traitement médicamenteux , Dermatoses faciales/anatomopathologie , Dermatoses faciales/traitement médicamenteux , Antibactériens/usage thérapeutique , Résultat thérapeutique , Épiderme/anatomopathologie , Érythème/anatomopathologie , Érythème/traitement médicamenteux , Nécrose
7.
Rev. chil. dermatol ; 30(2): 212-215, 2014.
Article Dans Espagnol | LILACS | ID: biblio-835954

Résumé

La rosácea es una dermatosis facial inflamatoria crónica caracterizada por periodos intermitentes de exacerbación y remisión. La etiología es desconocida y factores genéticos y ambientales están involucrados en su desarrollo. El tratamiento tópico y sistémico controla la rosácea en forma parcial. La Isotretinoína oral es útil por sus propiedades antiinflamatorias,inmunomoduladoras y de reducción del flujo sanguíneo.


Rosacea is a chronic facial inflammatory dermatoses characterized by intermittent periods of clinical exacerbation and remission. The etiology is unkown. Genetic and external factors are involved in the pathogenesis. Topical and oral treatments partially control the disease. Oral Isotretinoin can be useful because of the antiinflammatory, inmumodulating actions and because it reduce the blood flow.


Sujets)
Humains , Produits dermatologiques/administration et posologie , Isotrétinoïne/administration et posologie , Rosacée/traitement médicamenteux , Administration par voie orale
8.
Rev. Hosp. Clin. Univ. Chile ; 24(2): 150-157, 2013.
Article Dans Espagnol | LILACS | ID: biblio-996039

Résumé

Rosacea is a chronic inflammatory disease. Its frequency is higher in pale-skinned people and women over 30 years. Disease mechanisms include: abnormalities in innate immunity, inflammatory reactions to microorganisms, ultraviolet radiation damage, and vascular dysfunction. There are four clinical subtypes: erythematotelangiectatic, pustular papules, phymatous and ocular rosacea. Patients may present one or more characteristics of each subtypes. Injuries are classically located in midface area. Extreme temperatures, UV radiation, hot beberages, spicy foods, alcohol, exercise, topical irritants, psychological symptoms and drugs are associated to exacerbations. Clinical evaluation of the patient is usually enough for diagnosis. Nonpharmacologic interventions are essential for treatment. These include avoiding use of cosmetic, and triggers, skin care, and broad-spectrum sun protection. Patients with no response to general measures can respond to pharmacological agents. Topical metronidazole and azelaic acid are considered first-line treatments in mild to moderate disease. Oral tetracycline, have been used for many years for the treatment of papulopustular rosacea. Isotretinoin is useful in refractory disease. Treatment must be continous to maintain the response. (AU)


Sujets)
Humains , Mâle , Femelle , Rosacée/classification , Rosacée/diagnostic , Rosacée/traitement médicamenteux , Rosacée/thérapie
9.
Rev. méd. Chile ; 140(5): 637-639, mayo 2012. ilus
Article Dans Espagnol | LILACS | ID: lil-648592

Résumé

Background: Rosacea fulminans is a rare condition, characterized by a sudden onset of papulopustules, cysts, edema, and draining sinuses usually confined to the facial area. It is often accompanied by low-grade fever, myalgias and leukocytosis. Patients usually have a background of mild rosacea. We report two male patients aged 29 and 54 years, presenting with rosacea fulminans and ocular involvement, triggered by the use of topical steroids. Both responded to systemic treatment with corticosteroids, isotretinoin and metronidazole. Rosacea fulminans should be considered as a variant of rosacea that includes papulopustular, ocular, phymatous and erythematotelangiectatic types.


Sujets)
Adulte , Humains , Mâle , Adulte d'âge moyen , Hormones corticosurrénaliennes/effets indésirables , Maladies de l'oeil/induit chimiquement , Dermatoses faciales/induit chimiquement , Rosacée/induit chimiquement , Acné juvénile/diagnostic , Diagnostic différentiel , Dermatoses faciales/traitement médicamenteux , Rosacée/traitement médicamenteux
10.
Rev. chil. dermatol ; 28(4): 418-430, 2012. ilus, tab, graf
Article Dans Espagnol | LILACS | ID: lil-774869

Résumé

Introducción: La rosácea es un síndrome inflamatorio crónico frecuente que afecta principalmente la zona centrofacial. El subtipo más común, la rosácea eritematotelangiectásica (RET), no cuenta con un tratamiento efectivo demostrado. Estudios in vitro han propuesto que el factor de crecimiento endotelial (VEGF) podría tener un rol clave en la génesis de la rosácea al inducir angiogénesis. El uso exitoso de betabloqueadores orales (propanolol) y tópicos (timolol) en el hemangioma de la infancia abrió las puertas al estudio de la inhibición de la angiogénesis como principal objetivo terapéutico de las patologías vasculares benignas. Debido a que este subtipo de rosácea y los hemangiomas podrían presentar una etiopatogenia similar, se propone el estudio del efecto del timolol en este subtipo de rosácea. Metodología: Ensayo clínico randomizado doble ciego. Se reclutaron 67 pacientes con RET desde septiembre a diciembre de 2011. Se asignó un grupo con timolol tópico al 1 por ciento en base oil free y otro sólo con base oil free. Todos los pacientes recibieron instrucción y tratamiento estándar consistente en un limpiador, hidratante y protector solar. Nuestro outcome primario fue la diferencia de reducción del grado de eritema a las 12 semanas con colorímetro CR 200 de Minolta, y fue analizado según intención de tratar. Se evaluaron además las diferencias en las características clínicas, demográficas, el tamaño de las telangiectasias, la calidad de vida, evaluación subjetiva del tratamiento por el paciente, la adherencia a tratamiento y las reacciones adversas. Resultados: No hubo diferencia significativa en el grado de eritema a las 12 semanas de tratamiento entre los grupos, lo que permite rechazar la hipótesis diagnóstica. Tampoco se encontró diferencia alguna en los otros parámetros estudiados.


Introduction: Rosacea is a common chronic inflammatory syndrome that mainly affects the midface area. The most common subtype, Erythematotelangiectatic rosacea (ETR) has no proven effective treatment. Studies in vitro have suggested that vascular endothelial growth factor (VEGF) may have a key role in the pathogenesis of rosacea inducing angiogenesis. The successful use of oral (propanolol) and topical (timolol) betablockers in the childhood hemangioma conducted to the study of inhibition of angiogenesis as a main therapeutic target of benign vascular pathologies. Because this subtype of rosacea and hemangiomas share a similar pathogenesis, we proposed to study the effect of timolol in this subtype of rosacea. Methodology: Double blind randomized clinical trial. We recruited 67 patients with ETR from September to December of 2011. Two groups were assigned one with 1percent topical timolol oil free based and the other group used only the vehicle. All patients also received education and standard treatment consisting of a cleanser, moisturizer and sunscreen. The primary outcome was the difference in reducing the degree of erythema at week 12, and was evaluated through the Minolta CR 200 colorimeter and analyzed by intention to treat. Secondary outcomes were differences in clinical and demographic characteristics of the patients, the size of telangiectasias, quality of life, subjective evaluation from the patient, adherence to treatment and adverse reactions. Results: No significant difference was seen in the reduction of erythema degree at week 12 allowing us to reject the hypothesis. There were also no difference in all the other parameters. Conclusion: The present study shows that the use of topical timolol its not superior to placebo in reducing the degree of erythema or any of the variables analyzed. This study shows that topical timolol not constitute a possible treatment in ETR.


Sujets)
Humains , Mâle , Adulte , Femelle , Rosacée/complications , Rosacée/traitement médicamenteux , Timolol/administration et posologie , Administration par voie topique , Évolution Clinique , Méthode en double aveugle , Érythème/étiologie , Observance par le patient , Indice de gravité de la maladie , Facteurs temps , Timolol/effets indésirables , Facteurs de croissance endothéliale vasculaire
11.
RBM rev. bras. med ; 67(supl.4)jul. 2010.
Article Dans Portugais | LILACS | ID: lil-555293

Résumé

A rosácea é uma doença comum em adultos e tem uma apresentação muito variável. A doença com frequência produz eritema, pápulas, pústulas e edema na pele médio-facial.


Sujets)
Humains , Mâle , Femelle , Adulte , Maladies de la peau , Rosacée/chirurgie , Rosacée/diagnostic , Rosacée/traitement médicamenteux
14.
Medicina (B.Aires) ; 59(5,pt.1): 469-70, 1999.
Article Dans Espagnol | LILACS | ID: lil-247913

Résumé

Varón de 52 años que consulta por presentar disuria, ardor miccional y lesiones cutáneas que mejoran con una alta ingesta diaria de ácidos (vinagre y limón). En los últimos 20 años había consultado a diferentes profesionales sin encontrar la solución a su problema. Al suspender la ingesta de ácidos por indicación médica presentó disuria y lesiones cutáneas compatibles con rosácea. Por la asociación entre esta patología y la colonización gástrica com H. Pylori se realizó una endoscopia digestiva que confirmó su presencia. Se instituyó tratamiento específico con resolución completa y permanente de los síntomas. Se constató la erradicación a través de una nueva endoscopia digestiva con biopsia. Se sugiere que la conolización gástrica com H. Pylori podría estar relacionada com síntomas irritativos del tracto urinario inferior no aclarados por outra etiología.


Sujets)
Humains , Mâle , Adulte d'âge moyen , Acide acétique/usage thérapeutique , Amoxicilline/usage thérapeutique , Antibactériens/usage thérapeutique , Antiulcéreux/usage thérapeutique , Citrus/usage thérapeutique , Clarithromycine/usage thérapeutique , Infections à Helicobacter/traitement médicamenteux , Helicobacter pylori/isolement et purification , Oméprazole/usage thérapeutique , Pénicillines/usage thérapeutique , Rosacée/microbiologie , Troubles mictionnels/traitement médicamenteux , Rosacée/traitement médicamenteux
16.
Rev. chil. pediatr ; 68(4): 182-5, jul.-ago. 1997. ilus
Article Dans Espagnol | LILACS | ID: lil-207188

Résumé

La rosácea ocular es una dermatosis facial, frecuente en adultos, especialmente mujeres, cuya fisiopatología es aún mal comprendida, aunque parece relacionada a cambios vasomotores. La afección es infrecuente en niños y adolescentes, donde plantea probremas diagnósticos y terapéuticos. Presentamos un caso de rosácea infantil con compromiso ocular. La rosácea ocular se manifiesta con hiperhemia conjuntival, telangiectasias, meibomitis, chalazion, blefaritis, queratoconjuntivitis, vascularización corneal periférica e infiltración subepitelial, iritis y queratitis en los casos mas severos; el hallazgo más frecuente perece ser una blefaritis marginal


Sujets)
Humains , Mâle , Adolescent , Blépharite/complications , Rosacée/complications , Érythromycine/usage thérapeutique , Minocycline/usage thérapeutique , Rosacée/traitement médicamenteux
19.
Dermatología (Santiago de Chile) ; 10(4): 280-4, 1994. tab, ilus
Article Dans Espagnol | LILACS | ID: lil-144203

Résumé

Las bases dermatológicas son preparaciones semisólidas que están destinadas a la aplicación de medicamentos en forma externa. La prescripcón de recetas magistrales permite a los dermatológos individulaizar en forma adecuada las terapias de sus pacientes. Las bases pueden ser clasificadas según su composición en: bases oleaginosas, bases de absorción, emulsiones (aceite/agua, agua/aceite), bases hidrosolubles y geles. Por su bajo o nulo contenido en materia grasa, las bases más indicadas en acné o rosácea son las emulsiones de aceite en agua, las bases hidrosolubles, elaboradas con polietilenglicoles, y los geles. Es importante tener presente la posibilidad de interacciones o incompatibilidades entre diversos principios activos y las bases


Sujets)
Humains , Préparations Basiques , Préparation de médicament , Excipients pharmaceutiques/classification , Rosacée/traitement médicamenteux , Émulsions/analyse , Excipients/analyse , Gels/analyse , Concentration en ions d'hydrogène , Excipients pour pommade/analyse , Onguents/analyse , Sébum/métabolisme , Absorption cutanée
SÉLECTION CITATIONS
Détails de la recherche